13F value (AUM)
$11.5B
Ra Capital Management
RA CAPITAL MANAGEMENT, L.P.
$11.5B
13F long value · 2026-Q2Positions84
CategoryAsset Manager
Quarters tracked9
● #476 of 581 by 13F value
Size rank 2/10
15 NEW5 ADD4 TRIM17 EXIT
Snapshot
Ra Capital Management's 13F portfolio at a glance — size, concentration and this quarter's activity.
Positions
84 (10 unmapped)
Top 84 weight
100.0%
Quarters tracked
9
Latest 13F filed
Aug 14, 2026
New positions
15
Exits / near-exits
17
13F value by quarter
Total reported long value each quarter — fund flows plus market moves.
Top holdings — 2026-Q2
The fund's largest reported positions.
| Ticker | Issuer | Weight | Value | Shares | Since 2026-Q2 |
|---|---|---|---|---|---|
| — | ASCENDIS PHARMA A/S | 23.8% | $2.7B | 10.3M | — |
| PBLS | PARABILIS MEDICINES INC | 6.9% | $791.9M | 28.9M | — |
| RYTM | RHYTHM PHARMACEUTICALS INC | 6.4% | $740.2M | 6.7M | -23.3% |
| PCVX | VAXCYTE INC | 5.8% | $667.0M | 11.5M | +2.7% |
| SION | SIONNA THERAPEUTICS INC | 3.8% | $435.7M | 9.9M | -10.9% |
| TYRA | TYRA BIOSCIENCES INC | 3.4% | $389.6M | 12.2M | +15.6% |
| EWTX | EDGEWISE THERAPEUTICS INC | 3.0% | $341.0M | 8.4M | -24.6% |
| — | NEWAMSTERDAM PHARMA CO NV | 2.8% | $323.7M | 9.6M | — |
| COAG | HEMAB THERAPEUTICS HOLDINGS | 2.5% | $286.8M | 7.8M | — |
| SEPN | SEPTERNA INC | 2.0% | $234.3M | 7.0M | -25.1% |
| BCAX | BICARA THERAPEUTICS INC | 1.9% | $215.4M | 7.3M | -24.3% |
| MLYS | MINERALYS THERAPEUTICS INC | 1.8% | $207.6M | 7.7M | 0.0% |
| — | GH RESEARCH PLC | 1.8% | $205.3M | 7.6M | — |
| IRON | DISC MEDICINE INC | 1.6% | $179.2M | 2.5M | -5.9% |
| SGP | SPYGLASS PHARMA INC | 1.6% | $178.6M | 8.0M | +6.2% |
Quarterly changes — 2026-Q2
What Ra Capital Management opened, added, trimmed and exited this quarter, largest dollar moves first.
| Action | Ticker | Issuer | Prev shares | Curr shares | Change | Value Δ |
|---|---|---|---|---|---|---|
| NEW | — | ASCENDIS PHARMA A/S | — | 10.3M | — | +$2.7B |
| EXIT | ASND | ASCENDIS PHARMA A/S - ADR | 10.3M | 0 | -100.0% | -$2.4B |
| NEW | PBLS | PARABILIS MEDICINES INC | — | 28.9M | — | +$791.9M |
| NEW | COAG | HEMAB THERAPEUTICS HOLDINGS | — | 7.8M | — | +$286.8M |
| EXIT | DNTH | DIANTHUS THERAPEUTICS INC | 2.6M | 0 | -100.0% | -$219.2M |
| NEW | ABVX | ABIVAX SA-ADR | — | 1.1M | — | +$150.9M |
| NEW | ORKA | ORUKA THERAPEUTICS INC | — | 1.6M | — | +$148.0M |
| EXIT | PRAX | PRAXIS PRECISION MEDICINES I | 373.8K | 0 | -100.0% | -$120.4M |
| ADD | ARTV | ARTIVA BIOTHERAPEUTICS INC | 9.9M | 18.0M | +82.2% | +$110.7M |
| TRIM | NUVL | NUVALENT INC-A | 2.5M | 1.2M | -50.8% | -$105.7M |
Conviction over time
Portfolio weight of the current top long holdings, quarter by quarter — rising weight = growing conviction.